

I. Amendments to the Claims:

This Listing of Claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A pharmaceutical composition comprising hydrocodone or a pharmaceutically acceptable salt thereof and naltrexone or a pharmaceutically acceptable salt thereof, wherein

 said naltrexone or pharmaceutically acceptable salt thereof and said hydrocodone or pharmaceutically acceptable salt thereof are in a ratio of from 0.011:1 to 0.0125:1, and the pharmaceutical composition comprises from 0.055 to 0.28 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): The pharmaceutical composition of claim 1 comprising about 5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.055 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 3 (previously presented): The pharmaceutical composition of claim 1 comprising about 7.5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.0825 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 4 (previously presented): The pharmaceutical composition of claim 1 comprising about 10 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.11 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 5 (previously presented): The pharmaceutical composition of claim 1 comprising about 15 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.165 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 6 (previously presented): The pharmaceutical composition of claim 1 comprising about 20 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.22 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 7 (previously presented): The pharmaceutical composition of claim 1 comprising about 5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.0625 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 8 (previously presented): The pharmaceutical composition of claim 1 comprising about 7.5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.09375 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 9 (previously presented): The pharmaceutical composition of claim 1 comprising about 10 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.125 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 10 (previously presented): The pharmaceutical composition of claim 1 comprising about 15 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.1875 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 11 (previously presented): The pharmaceutical composition of claim 1 comprising about 20 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.25 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 12 (previously presented): The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of said hydrocodone or pharmaceutically acceptable salt thereof.

Claim 13 (previously presented): The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 14 (previously presented): The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of said hydrocodone or pharmaceutically acceptable salt thereof and said naltrexone or pharmaceutically acceptable salt thereof.

Claim 15 (previously presented): The pharmaceutical composition of claim 12, wherein the composition provides effective pain relief for at least 12 hours after steady state oral administration to human patients.

Claim 16 (previously presented): The pharmaceutical composition of claim 12, wherein the composition provides effective pain relief for at least 24 hours after steady state oral administration to human patients.

Claim 17 (previously presented): The pharmaceutical composition of claim 14, wherein said hydrocodone or pharmaceutically acceptable salt thereof and said naltrexone or pharmaceutically acceptable salt thereof are substantially interdispersed in said sustained release excipient.

Claim 18 (previously presented): The pharmaceutical composition of claim 1, wherein said hydrocodone is in the form of the bitartrate salt.

Claim 19 (previously presented): The pharmaceutical composition of claim 1, wherein said naltrexone is in the form of the hydrochloride salt.

Claim 20 (previously presented): The pharmaceutical composition of claim 1 further comprising a non-steroidal anti-inflammatory drug selected from the group consisting of ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen,

pioprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mfenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, disflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, pharmaceutically acceptable salts thereof and mixtures thereof.

Claim 21 (previously presented): A method of treating pain in a human patient comprising orally administering a pharmaceutical composition according to claim 1.

Claim 22 (previously presented): A method of preparing a pharmaceutical composition comprising combining about 5 to about 20 mg hydrocodone or a pharmaceutically acceptable salt thereof and 0.055 to 0.28 mg naltrexone or a pharmaceutically acceptable salt thereof into an oral dosage form, said naltrexone or pharmaceutically acceptable salt thereof and said hydrocodone or pharmaceutically acceptable salt thereof in a ratio of from 0.011:1 to 0.0125:1.

Claim 23 (previously presented): A method of deterring abuse of a hydrocodone composition comprising preparing a pharmaceutical composition according to claim 1.

Claim 24 (previously presented): A method of treating pain in a human patient comprising administering a pharmaceutical composition according to claim 27 to said patient.

Claim 25 (previously presented): The method of claim 24, wherein the dosage form is administered once-a-day.

Claim 26 (previously presented): The method of claim 24, wherein the dosage form is administered twice-a-day.

Claim 27 (previously presented): A pharmaceutical composition comprising hydrocodone or a pharmaceutically acceptable salt thereof and naltrexone or a pharmaceutically acceptable salt

Response dated November 24, 2010

Reply to the Office Action mailed on June 24, 2010

thereof, wherein said naltrexone or pharmaceutically acceptable salt thereof and said hydrocodone or pharmaceutically acceptable salt thereof are in a ratio of 0.0125:1.

Claim 28 (previously presented): The pharmaceutical composition of claim 27, wherein the drugs in the composition consist of said naltrexone or pharmaceutically acceptable salt thereof and said hydrocodone or pharmaceutically acceptable salt thereof.

Claim 29 (previously presented): The pharmaceutical composition of claim 27 comprising from about 5 to about 20 mg of said hydrocodone or pharmaceutically acceptable salt thereof.

Claim 30 (previously presented): The pharmaceutical composition of claim 27 comprising 0.0625 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 31 (previously presented): The pharmaceutical composition of claim 27 comprising 0.09375 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 32 (previously presented): The pharmaceutical composition of claim 27 comprising 0.125 mg of the naltrexone or pharmaceutically acceptable salt thereof.

Claim 33 (previously presented): The pharmaceutical composition of claim 27 comprising 0.1875 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 34 (previously presented): The pharmaceutical composition of claim 27 comprising 0.25 mg of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 35 (previously presented): The pharmaceutical composition of claim 27 which provides sustained release of said naltrexone or pharmaceutically acceptable salt thereof.

Claims 36 (previously presented): The pharmaceutical composition of claim 1 in the form of an osmotic dosage form.

Claim 37 (new): The pharmaceutical composition of claim 36, wherein the osmotic dosage form comprises a drug layer and a push layer, and said hydrocodone or pharmaceutically acceptable salt thereof and said naltrexone or a pharmaceutically acceptable salt thereof are contained in the drug layer.

Claim 38 (new): The pharmaceutical composition of claim 1, wherein said naltrexone is naltrexone hydrochloride dihydrate.